Merck & Co. Receives Consensus Recommendation of “Buy” from Brokerages (NYSE:MRK)
Shares of Merck & Co. (NYSE:MRK) have received a consensus recommendation of “Buy” from the sixteen brokerages that are covering the stock, AnalystRatings.NET reports. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $58.20.
Several analysts have recently commented on the stock. Analysts at Bank of America reiterated a “buy” rating on shares of Merck & Co. in a research note on Thursday. They now have a $62.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Merck & Co. to $61.00 in a research note on Monday, April 14th. They now have a “hold” rating on the stock. Finally, analysts at MKM Partners raised their price target on shares of Merck & Co. from $64.00 to $70.00 in a research note on Friday, April 11th. They now have a “buy” rating on the stock.
Shares of Merck & Co. (NYSE:MRK) opened at 57.4775 on Friday. Merck & Co. has a 1-year low of $44.60 and a 1-year high of $58.32. The stock has a 50-day moving average of $56.22 and a 200-day moving average of $51.74. The company has a market cap of $169.0 billion and a price-to-earnings ratio of 39.14.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.88 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter last year, the company posted $0.83 earnings per share. Merck & Co.’s revenue was down 3.6% compared to the same quarter last year. Analysts expect that Merck & Co. will post $3.44 EPS for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.